MYGN Myriad Genetics
- 25.100
- -0.370-1.45%
Myriad Genetics News
Form 144 | Myriad Genetics(MYGN.US) Director Proposes to Sell 156.86K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Myriad Genetics(MYGN.US)$ Director Newcomer Lee Nisley intends to sell 6,200 shares of its common stock on May 13, with a total market value of approximately $156.86K.
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $28
Piper Sandler analyst John Peterson maintains Myriad Genetics with a Neutral and raises the price target from $23 to $28.
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Shares Bounce 26% But Its Business Still Trails The Industry
Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Looking back a bit furthe
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
Investors Bid Myriad Genetics (NASDAQ:MYGN) up US$428m Despite Increasing Losses YoY, Taking One-year Return to 36%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can significantly boost your returns by picking above-average stocks. To wit, the Myriad
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing around 0.3%. The iShares Biotechnology ETF (IBB
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Price Target Raised to $35.00/Share From $25.00 by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Myriad Genetics Raised to Outperform From Market Perform by Leerink Partners
Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35
Leerink Partners analyst Puneet Souda upgrades Myriad Genetics from Market Perform to Outperform and raises the price target from $25 to $35.
Myriad Genetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 55.83% Leerink Partners $25 → $35 Upgrades Market Perform → Outperform 01/30/2024 38.02% Goldma
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estim
Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue
Myriad Genetics (MYGN) shares rose more than 13% in recent Wednesday trading, a day after the company reported a narrower Q1 adjusted loss and higher revenue. The company reported an adjusted loss lat
Myriad Genetics Shares Rise 15% After 1Q Revenue Beats Estimates
By Chris Wack Myriad Genetics shares were up 15% to $22.66 after the company reported first-quarter revenue that beat analysts' expectations. The genetic testing company reported quarterly revenue o
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
Myriad Genetics Surges 17% as Street Applauds 2024 Guidance, Q1 Results
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday.Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply during Wednesday's session following better-than-expec
Analysis
Price Target
No Data
